Literature DB >> 12657128

Hysteroscopy does not increase the risk of microscopic extrauterine spread in endometrial carcinoma.

L Selvaggi1, G Cormio, O Ceci, G Loverro, A Cazzolla, S Bettocchi.   

Abstract

Fluid hysteroscopy has been suspected to cause tumor dissemination in the abdominal cavity in endometrial cancer patients. The aim of our study was to evaluate the incidence of microscopic extrauterine spread according to diagnostic modality (dilatation & curretage, D&C, hysteroscopy, or both) in patients with endometrial carcinoma. A retrospective study was conducted on 147 patients with histologically proven diagnosis of endometrial carcinoma without macroscopic extrauterine disease. Fluid hysteroscopy was performed by using saline solution irrigated at a final flow of 150 ml/min with a intrauterine pressure ranging between 25 and 50 mmHg. Microscopic intraperitoneal disease and positive peritoneal cytology were considered the primary end-points of this analysis. Fifty-two patients (35%) had diagnosis of endometrial cancer made only by D&C, 56 (39%) underwent D&C and then hysteroscopy, and 39 (26%) had only hysteroscopy. Distribution of the patients in this three groups was casual, and clinicopathologic characteristics of the patients in the three groups were similar. Peritoneal cytology was positive in nine patients, 13 had microscopic ovarian metastases, and eight had microscopic involvement of the pelvic peritoneum or of omentum. Neither the presence of positive peritoneal cytology nor the findings of microscopic intraperitoneal dissemination were significantly associated with the diagnostic procedure employed for primary diagnosis (D&C or D&C plus hysteroscopy or hysteroscopy alone). We conclude that fluid hysteroscopy does not increase the risk of microscopic intraperitoneal spread in endometrial cancer patients as compared to D&C.

Entities:  

Mesh:

Year:  2003        PMID: 12657128     DOI: 10.1046/j.1525-1438.2003.13044.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  Does duration of hysteroscopy increase the risk of disease recurrence in patients with endometrial cancer? A multi-centre trial.

Authors:  Clemens Tempfer; Georg Froese; Bernd Buerkle; Stephan Polterauer; Christoph Grimm; Nicole Concin; Gerda Hofstetter; Monika Weigert; Martin K Oehler
Journal:  Exp Ther Med       Date:  2011-06-30       Impact factor: 2.447

Review 2.  Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer.

Authors:  Jeong-Yeol Park; Joo-Hyun Nam
Journal:  Oncologist       Date:  2015-02-11

3.  Sentinel lymph node detection following the hysteroscopic peritumoural injection of 99mTc-labelled albumin nanocolloid in endometrial cancer.

Authors:  Marco Maccauro; Giovanni Lucignani; Gianluca Aliberti; Carlo Villano; Maria Rita Castellani; Eugenio Solima; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12-30       Impact factor: 9.236

4.  Incidence of positive peritoneal cytology in patients with endometrial carcinoma after hysteroscopy vs. dilatation and curettage.

Authors:  Andraz Dovnik; Bojana Crnobrnja; Branka Zegura; Iztok Takac; Maja Pakiz
Journal:  Radiol Oncol       Date:  2016-05-30       Impact factor: 2.991

5.  Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma.

Authors:  Fangfang Wang; Aijun Yu; Haichao Xu; Xiaojing Zhang; Li Li; Hanmei Lou; Hua Yu; Jun Lin
Journal:  Int J Gynecol Cancer       Date:  2017-11       Impact factor: 3.437

Review 6.  Preoperative assessment of endometrial cancer.

Authors:  Péter Török; Zoárd Krasznai; Szabolcs Molnár; Rudolf Lampé; Attila Jakab
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.